Yunnan Botanee Bio-Technology Group Co.LTD: history, ownership, mission, how it works & makes money

From its 2010 founding as Kunming Botanee Bio-Technology to a ChiNext listing in 2021 (stock code 300957), Yunnan Botanee Bio-Technology Group has parlayed early moves-launching Winona on Tmall in 2011, building an R&D center in 2013 and securing Sequoia investment in 2014-into a vertically integrated skin-health platform that blends dermatology, botany and e-commerce; today the company trades with 419.95 million shares outstanding and a market capitalization near 17.05 billion CNY (as of Dec 5, 2025), maintains a conservative debt-to-equity ratio of 0.13 and an Altman Z‑Score of 7.68, operates two main segments (Skin Care Products and Medical Instruments) and channels sales through both online marketplaces and offline pharmacy and retail networks, and reported operating revenue of 2.805 billion CNY in 2024 with net profit attributable to shareholders of 484 million CNY-backed by a 156.89 million share float, 2.62% insider ownership and 7.82% institutional holdings-while positioning Winona's patented, GMPC‑compliant formulations and medical-device offerings for deeper penetration in lower‑tier Chinese cities and Southeast Asian markets.

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ): Intro

• 2010 - Kunming Botanee Bio-Technology Co., Ltd. established, marking entry into skincare and cosmetics.
• 2011 - Launched Winona online flagship store on Tmall, beginning large-scale e-commerce distribution.
• 2013 - Founded R&D Center and subsidiary Shanghai Botanee Bio-Technology Co., Ltd., strengthening product development and regulatory capability.
• 2014 - Received strategic investment from Sequoia Capital, enhancing capital base and growth resources.
• 2015 - Awarded national high-tech enterprise certification; Winona became the first Chinese brand to appear at the World Congress of Dermatology.
• 2021-03-25 - Listed on Shenzhen Stock Exchange ChiNext (stock code: 300957), the first listed Chinese company focused on functional skin-care products.

• Major shareholders: founding team and management, strategic institutional investors (including Sequoia Capital as an early investor) and public float following ChiNext listing.
• Corporate governance: board of directors with independent directors, professional executive management with cross-disciplinary expertise in dermatology, R&D and e-commerce operations.

• Mission: develop clinically effective, safety-first skincare for sensitive and problem-prone skin using botanical resources and evidence-based R&D.
• R&D orientation: clinical dermatology collaboration, formulation safety testing, product efficacy trials and regulatory compliance for topical medical-adjacent skincare.
• Assets: R&D center (est. 2013), clinical partnerships, manufacturing cooperation and an IP portfolio of formulations and technical processes.

• Product development: in-house R&D plus clinical validation; focus on formulations for sensitive skin and barrier repair.
• Manufacturing: outsourced and in-house controlled production meeting cosmetic and higher-safety standards.
• Sales & distribution: multi-channel - direct e-commerce (Tmall, JD, company site), social commerce (WeChat, short video platforms), pharmacy/OTC channels and selected offline retail/dermatology clinics.
• Marketing: brand marketing emphasizing clinical credibility, KOLs and e-commerce performance marketing; participation in medical/dermatology forums to bolster trust.

• Primary revenue: sale of finished skincare products under Winona and sub-brands via e-commerce and offline channels.
• Secondary revenue: OEM/ODM services, authorized distribution to pharmacy channels and professional dermatology/clinic partnerships.
• Margin drivers: product mix (premium vs. mass SKUs), channel mix (direct e‑commerce yields higher gross margin), scale in procurement and manufacturing efficiency, and R&D-driven differentiated SKUs that command price premiums.

• Strengths: strong sensitive-skin brand recognition (Winona), e-commerce capability, clinical positioning, investment backing and R&D infrastructure.
• Risks: regulatory changes, competition from domestic and international dermatological/cosmetic players, ingredient supply volatility, and channel/marketing cost pressures (ad spend and KOL costs).

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ): History

• Primary business: cultivation of medicinal herbs, botanical extraction, formulation and sale of active botanical ingredients and nutraceuticals.
• Growth drivers: expanded cultivation acreage, increased extraction output, product diversification into high-value botanicals and pharma intermediates.
• Recent capital/market status: steady share performance and conservative leverage supporting capacity investments.

• Ownership profile: a relatively small insider stake (2.62%) and modest institutional holdings (7.82%) suggest a widely held free float with 156.89 million shares available for trading, supporting liquidity for investors.
• Financial posture: debt-to-equity of 0.13 and an Altman Z-Score of 7.68 point to conservative leverage and low bankruptcy risk, enabling long-term investment in production capacity and R&D.
• How it makes money: margin capture occurs across the value chain - selling extracted active ingredients and finished botanicals domestically and internationally, plus contract manufacturing for partners.

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ): Ownership Structure

• Mission: Create China's skin health ecosystem by integrating R&D, production and marketing in the "Internet Plus" skin-health sector.
• Vision: Bring health and beauty to everyone; build China's leading dermatological-grade skin-care platform.
• Core values:
  • Pursuit of Excellence
  • Simplicity and Transparency
  • Result Orientation
  • Diligence and Dedication
  • Gratitude and Goodwill
  • Integrity and Pragmatism
• Quality & technology focus: use of dermatology, biotechnology and botanical extraction; Winona implements patented technologies and dermatological-grade gentle formulas; GMP-C cosmetics standards for export-ready quality (US/EU comparable).

• Integrated model: in-house R&D → patented ingredient/formula development → GMP/GMPC-standard manufacturing → multi-channel sales (e‑commerce, TCM/derm clinics, retail partners).
• Revenue streams:
  • Brand product sales (Winona and sub-brands) - primary revenue driver.
  • OEM/ODM and technology licensing - incremental margins from capacity utilization and patents.
  • Clinical/dermatological services and channel partnerships in medical aesthetics/skin clinics.
• Digital-first distribution: heavy emphasis on direct-to-consumer e-commerce and social marketing to drive unit economics and customer lifetime value (repeat purchase rates are a key KPI).

• Founders and management maintain a significant stake, aligning incentives with long-term brand and R&D investment.
• Institutional holders and strategic investors comprise the remainder, providing capital for channel expansion and manufacturing scale-up.
• Public float allows retail investor participation; trading ticker: 300957.SZ.

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ): Mission and Values

• Core operational model: end-to-end integration from R&D (formulation, clinical validation) to manufacturing (GMP-capable facilities) to marketing and after-sales service.
• Digital strategy: 'Internet Plus' initiatives to drive e-commerce, digital marketing, livestreaming sales, and data-driven product iteration.
• Clinical and medical pathway: development of skin-care-related medical devices and post-procedure care products to bridge cosmetic and medical markets.

• Skin Care Products: consumer-facing portfolio including creams, lotions, masks, essences and makeup items (BB creams, isolation creams, removers).
• Medical Instruments & Devices: medical-grade skin-care products such as hyaluronic acid repair films, dressings and protective materials used in sensitive-skin management and post-procedure wound care.

• Online: company stores on major e-commerce platforms, livestreaming, official webstore and digital marketing funnels.
• Offline: self-operated stores and counters, third-party retail partners, salon/professional channels.
• Distribution/Entrusted Parties: regional distributors and entrusted manufacturing/marketing partners for specialized lines and clinical device placements.

• Self-built 'Viennona counter service platform' store operating income (2024): 181.7272 million yuan, representing ~6.51% of the company's main business income.
• Implied main business income (2024) ≈ 2,793.1 million yuan (181.7272 / 0.0651 ≈ 2,793.1 million).

• Product sales (consumer skincare and makeup) - primary revenue engine via e-commerce and retail counters.
• Medical-device sales and institutional contracts - higher-margin, regulated channels supplying clinics and hospitals.
• Channel diversification - combining proprietary retail/counter platforms (Viennona) with distributor networks to scale reach and reduce single-channel concentration risk.
• Value-added services - post-sales skin health programs, professional training for partners, and B2B product development/contract manufacturing.

• Discovery & formulation → clinical/dermatological validation → pilot production → mass manufacturing → multi-channel launch.
• Feedback loops from e-commerce and counters inform rapid product iteration and targeted marketing campaigns under the 'Internet Plus' model.

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ): How It Works

• Founded in Yunnan province, Botanee evolved from a traditional herbal and botanical research base into a listed specialty skincare and medical-device group (stock code 300957.SZ).
• Ownership structure: public shareholders with significant holdings by founding/controlling shareholders and management; listed on the Shenzhen Stock Exchange.
• Strategic vertical integration: in-house R&D, production, brand management, clinical/dermatological partnerships and direct retail channels.

• Mission: develop dermatologically validated, botanically informed skincare and medical-device solutions focused on sensitive skin, pediatric care and clinical efficacy.
• Values: safety, evidence-based innovation, dermatologist collaboration and consumer trust.
• Related corporate articulation: Mission Statement, Vision, & Core Values (2026) of Yunnan Botanee Bio-Technology Group Co.LTD.

• R&D and product development: centralized labs in Yunnan combining botanical extraction, dermatological testing and medical-device design.
• Manufacturing: company-owned GMP/medical-grade production lines for cosmetics and registered medical devices to control quality and margins.
• Marketing & distribution: omnichannel strategy - e-commerce platforms, self-operated "Viennona counter service platform" stores, physician/dermatologist recommendations, and traditional retail partners.
• Brand portfolio management: multiple brands targeting distinct segments (sensitive adult skin, baby skin, clinical products, general cosmetics).

• Product sales: primary revenue from skincare and cosmetic product lines - Winona, Winona Baby, AOXMED, Beforteen, Za, and PURE&MILD.
• Medical device sales and clinical supplies: registered medical/OTC devices sold to clinics and through retail channels.
• Direct retail and own-channel monetization: self-built Viennona counter service platform stores providing higher-margin direct sales and consumer data capture.
• E-commerce & platform partnerships: third-party e-commerce marketplaces and brand stores drive volume and reach; dermatologist recommendations drive clinical credibility and repeat purchases.
• Service and licensing: select product licensing, co-branding or clinical partnerships contribute incremental revenue.

• Brand diversification: multiple brands spanning mass-market cosmetics to clinically positioned products reduce single-brand risk and expand TAM.
• Channel mix: combination of higher-margin owned channels (Viennona stores, official e-shop) and high-volume third-party e-commerce.
• Clinical endorsement: dermatologist recommendations and medical-device registration increase conversion and allow premium pricing for clinical series (e.g., AOXMED).
• R&D pipeline and product renewal: continual launches and formulation upgrades to drive repeat purchase and basket size.

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ): How It Makes Money

• Core product sales: facial care, body care and targeted dermatological skincare under Winona.
• Counter & specialty store retail: self-built Viennona counter service platform and pharmacy counters.
• E-commerce and new retail: flagship stores on major platforms, social commerce, livestreaming and AI-driven customer targeting.
• International and distributor channels: exploration of Southeast Asian markets and partnerships for cross-border sales.

• Pharmaceutical channel roots provide trust and shelf placement in drugstores and medical beauty outlets.
• Heavy use of Internet efficiency and mainstream e-commerce traffic to scale direct-to-consumer sales rapidly.
• New media marketing and AI enable precise customer acquisition and retention, improving unit economics.
• Product-line expansion (Winona), deeper penetration in lower-tier Chinese cities, and targeted international rollout (Southeast Asia) to sustain growth.